U.S. markets close in 3 hours 56 minutes
  • S&P 500

    3,900.94
    +89.79 (+2.36%)
     
  • Dow 30

    31,612.84
    +680.47 (+2.20%)
     
  • Nasdaq

    13,525.78
    +333.43 (+2.53%)
     
  • Russell 2000

    2,264.83
    +63.78 (+2.90%)
     
  • Crude Oil

    61.44
    -0.06 (-0.10%)
     
  • Gold

    1,731.40
    +2.60 (+0.15%)
     
  • Silver

    26.90
    +0.46 (+1.74%)
     
  • EUR/USD

    1.2061
    -0.0026 (-0.22%)
     
  • 10-Yr Bond

    1.4410
    -0.0190 (-1.30%)
     
  • GBP/USD

    1.3942
    +0.0020 (+0.14%)
     
  • USD/JPY

    106.6570
    +0.1550 (+0.15%)
     
  • BTC-USD

    49,097.31
    +5,661.36 (+13.03%)
     
  • CMC Crypto 200

    982.80
    +54.57 (+5.88%)
     
  • FTSE 100

    6,588.53
    +105.10 (+1.62%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

Arcus Biosciences to Participate in Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the following upcoming 2021 virtual investor conferences:

  • 10th Annual SVB Leerink Global Healthcare Conference, Friday, February 26 at 12:00 pm ET

  • Cowen 41st Annual Health Care Conference, Tuesday, March 2 at 11:10 am ET

  • Barclays Global Healthcare Conference, Wednesday, March 10 at 1:15 pm ET

A live audio webcast of each presentation will be available by visiting the "Investors" section of the Arcus website at www.arcusbio.com. A replay of each webcast will be available for at least two weeks following the live event.

About Arcus Biosciences

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has four molecules in clinical development: Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1-high metastatic non-small cell lung cancer (NSCLC) evaluating zimberelimab monotherapy, domvanalimab with zimberelimab and domvanalimab plus AB928 with zimberelimab. In addition, domvanalimab is advancing into ARC-10, Arcus’s "two in one trial" to support the potential approvals of both zimberelimab and zimberelimab + domvanalimab and a registrational study, in collaboration with AstraZeneca, evaluating the curative-intent stage III NSCLC setting. AB308, an anti-TIGIT antibody that is FcR enabled, is advancing into clinical development to investigate additional indications, with a focus on hematological malignancies. Zimberelimab (AB122), Arcus’s anti-PD-1 monoclonal antibody, was in-licensed to enable the development of Arcus’s combination regimens and is being evaluated in various combinations across the portfolio. For more information about Arcus Biosciences, please visit www.arcusbio.com.

Source: Arcus Biosciences

View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005864/en/

Contacts

Katherine Bock
VP Investor Relations & Corporate Strategy
(510) 694-6231
kbock@arcusbio.com